Is CBD legal in Germany? Read BfArM’s reply to CBDkaufen.com
BERLIN, GERMANY / ACCESSWIRE / May 6, 2019 / Since January 2019 there have been several seizures of CBD-Shops throughout Europe. CBD, a non-psychoactive component of the Cannabis plant, however, does not fall under the Narcotic Laws of Europe, as far as it complies to certain criteria.
In Germany, however, the online shop CBDKaufen.com has asked the “Federal Institute for Drugs and Medical Devices” (BfArM), the body responsible for declaring the legal status of products in Germany, whether or not CBD-Oils is legal in Germany and if CBD products can be sold freely in Germany.
According to C. Badde of CBDkaufen.com, “our goal is to demystify the complex legal issues surrounding the distribution of cannabidiol products and make sure business owners and consumers are operating within the legal safety net.”
In response to CBDkaufen.com’s request, BfArM released its statement on the legal status of CBD in Germany:
“With the Act on the Amendment of Narcotic Law and Other Regulations, which came into effect on 10.03.2017, the legislator changed the position of cannabis in Annexes I to III to section 1 Paragraph 1 of the Narcotic Law (BtMG) in Germany. Since then, the Narcotics Act has distinguished between cannabis in Annex III (use for medical purposes) and cannabis in Annex I (use for non-medical purposes). Annex I also provides for exemptions for hemp (see letters b and d under the heading cannabis).
According to letter b under the position Cannabis in Annex I to § 1 paragraph 1 BtMG, plants and plant parts of plants belonging to the genus Cannabis are excluded from the narcotic regulations if they originate from cultivation in countries of the European Union with certified seeds ( industrial hemp) or their content of THC does not exceed 0.2 % and the trade with them (except cultivation) serves exclusively commercial or scientific purposes which exclude a possibility for abuse for intoxication purposes.
This derogation shall also apply to preparations of the plants or parts of plants if they comply with the above conditions.
Since the free trade is restricted to commercial or scientific purposes, unprocessed or processed (e.g. only dried and crushed) parts of plants may not be sold to the end consumer.
This does not apply to preparations with processed industrial hemp of the above-mentioned varieties, even if they still contain small THC residues from the plant parts. However, the condition for sale to the end consumer is that abuse for intoxication purposes can be ruled out. The limit values of the BfR can be invoked here if oral ingestion of the product is intended.
The cannabis extracts requested by CBDKaufen.com (CBD Oil, CBD-Isolate and other Cannabidiol Extracts) may – from a narcotics law point of view – only be sold to the end consumer if the extracts were obtained exclusively from industrial hemp (
Israel expects $220 million in non-defence trade with Bahrain in 2021
Royal Bank, National Bank of Canada profit beat estimates on lower than expected provisions
North Korea-linked hackers targeted J&J, Novavax in hunt for COVID research
WRAPUP 1-Royal Bank, National Bank of Canada profit beat estimates on lower than expected provisions
UK approval of COVID-19 vaccine won’t affect Germany’s doses – ministry
Merck Sells Equity Stake in Moderna Following Record Gains For Coronavirus Vaccine Maker
Merck & Co, an early investor in coronavirus vaccine maker Moderna, has sold its equity stake following a record year of gains for the Cambridge, Massachusetts-based biotech.
3 Airline Stocks Ready for Takeoff
Airlines stocks have shown signs of a turnaround over the last month. Here are three to put on the radar.
Tesla CEO says he is open to friendly deal with rival carmaker
Tesla Chief Executive Elon Musk on Tuesday said he was open to discussing a merger of his start-up electric carmaker with a rival. Speaking at an Axel Springer event in Berlin, Musk was asked whether he would consider buying a rival carmaker given that Tesla’s market value of more than $500 billion would make it easy to launch a takeover bid.
Workhorse Shares Fall On Delayed USPS Mail Truck Decision
Shares of Workhorse Group (NASDAQ: WKHS) are down in after-hours trading Tuesday on news of a delay for the long-awaited U.S. Postal Service contract.What Happened: The USPS is delaying its contract decision on the USPS replacement vehicles, according to Trucks.com.The USPS told Trucks it expects to make a decision in the second fiscal quarter of 2021. This decision has been delayed multiple times already and now puts pressure on Workhorse, one of three finalists for the contact.”Amid continuing Covid-19 concerns, and in order to provide for capital investment activities and required approvals, the program schedule has been revised and a decision is now planned for quarter 2 of fiscal year 2021,” the USPS said in a statement.Related Link: Workhorse CFO Steve Schrader On The Status Of The USPS ContractWhy It’s Important: The USPS is set to award a $6 billion contract for 180,000 delivery vehicles. Workhorse Group is one of the finalists along with Turkey-based Krsan and Oshkosh Corporation (NYSE: OSK).Shares of Workhorse are up over 700% in 2020 and investors could sell the delay news.WKHS Price Action: Shares of Workhorse fell 14% to $21.75 in after-hours trading.See more from Benzinga * Click here for options trades from Benzinga * Why Barstool, MGM Could Be Big Winners With Michigan Online Sports Betting * Musk Wants Tesla Employees To Pinch Pennies For Profitability(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
How to Avoid Paying Taxes on Inherited Property
Inheriting a home or other property can increase the value of your estate but it can also result in tax consequences. If the property you inherit has appreciated in value since the original owner purchased it, you could be on … Continue reading ->The post How to Avoid Paying Taxes on Inherited Property appeared first on SmartAsset Blog.
A ‘severe’ drop is imminent, this stock market is signaling, says contrarian strategist
Investors are crowding into the stock market right now, and they aren’t seeing the big signals that indicate they are about to get caught up in a rough period of selling, says our call of the day from contrarian investor Steven Jon Kaplan.
Li Auto’s stock erases gains after delivery data, as other China-based EV makers keep falling
Shares of Li Auto Inc. reversed course to trade slightly lower Wednesday, even after the Beijing-based company reported a monthly record of deliveries in November, as the stocks of other China-based electric vehicle makers continued to pull back.
Dow Jones Futures Fall Amid Pfizer Coronavirus Vaccine Approval; Apple Hits New Buy Point
Dow Jones futures were in focus early Wednesday after Apple hit a new buy point. AMD, PayPal and Facebook are in or near buy zones.
Dow Jones Loses Ground Late As McConnell Shoots Down Stimulus Plan; Tesla Gains Again
The Dow Jones gave up gains late after Senate Majority Leader Mitch McConnell shot down a proposed coronavirus stimulus plan.
2 Big Dividend Stocks Yielding 10%; Raymond James Says ‘Buy’
Dividend stocks are the Swiss army knives of the stock market.When dividend stocks go up, you make money. When they don’t go up — you still make money (from the dividend). Heck, even when a dividend stock goes down in price, it’s not all bad news, because the dividend yield (the absolute dividend amount, divided by the stock price) gets richer the more the stock falls in price.Knowing all this, wouldn’t you like to find great dividend stocks? Of course you would. Raymond James analysts have chimed in – and they are recommending two high-yield dividend stocks for investors looking to find protection for their portfolio. These are stocks with a specific set of clear attributes: a dividend yield of 10% and Strong Buy ratings.Kimbell Royalty Partners (KRP)We’ll start with Kimbell Royalty Partners, a land investment company operating in some of the US’ major oil and gas producing regions: the Bakken of North Dakota, Pennsylvania’s Appalachian region, the Colorado Rockies, and several formations in Texas. Kimbell owns mineral rights in more than 13 million acres across these regions, and collects royalties from over 95,000 active wells. Over 40,000 of those wells are in the Permian Basin of Texas, the famous oil formation that has, in the past decade, helped turn the US from a net importer of hydrocarbons to a net exporter.The coronavirus crisis hit Kimbell directly in the pocketbook, knocking down share prices and earnings as economic restrictions, social lockdowns, and the economic downturn all struck at production and demand. The situation has only begun to revive, with the Q3 revenues growing 44% sequentially to reach $24.3 million.Kimbell has long been a reliable dividend payer, with a twist. Where most dividend stocks keep their payouts stable, typically making just adjustment in a year, Kimbell has a history of reevaluating its dividend payment every quarter. The result is a dividend that is rarely predictable – but is always affordable for the company. The last declaration, for the third quarter, was 19 cents per common share, or up 46% from the previous quarter. At that rate, the dividend yields
10%,Covering the stock for Raymond James, analyst John Freeman noted, “Despite a strong quarterly performance and a nearly 50% distribution raise in 3Q, the market continues to under appreciate the unique value proposition of Kimbell’s assets, in our view. Kimbell has a best-in-class 13% base decline, exposure to every major basin and commodity, as well as a very manageable leverage profile…”Regarding the possible anti-hydrocarbon stance of a Biden Administration, Freeman sees little reason for worry, saying, “Investors concerned about a potential Biden presidency (which appears increasingly likely) have little to fear in KRP. The company has less than
2% of acreage on federal lands, meaning a frac ban on those properties would not have a material impact on KRP’s business and might actually help them if it improved the overall supply impact.”In line with these comments, Freeman rates KRP a Strong Buy, and his $9 price target implies it has room for 25% growth going forward. (To watch Freeman’s track record, click here)Wall Street appears to agree with Freeman, and the analyst consensus view is also a Strong Buy, based on 5 unanimous positive reviews. This stock is priced at $7.21, and its $11 average target is even more bullish than Freemans, suggesting a one-year upside of
52%. (See KRP stock analysis on TipRanks)NexPoint Real Estate Finance (NREF)NexPoint inhabits the real estate trust niche, investing in mortgage loans on rental units, both single- and multi-family occupancy, along with self-storage units and office spaces. The company operates in the US, across major metropolitan hubs.NexPoint held its IPO in February this year, just before the coronavirus pandemic inspired an economic crisis. The offering saw 5 million shares sell, and brought in some $95 million in capital. Since then, the shares are down 13%. Earnings, however, have posted gains in each full quarter that the company has reported as a public entity, coming in at 37 cents per share in Q2 and 52 cents in Q3. The Q3 number was 30% above the forecast.The dividend here is also solid. NexPoint started out with a 22-cent per share payment in Q1, and raised it in Q2 to its current level of 40 cents per common share. This annualizes to $1.60, making the yield an impressive
10%.Stephan Laws, 5-star analyst with Raymond James, is impressed with what he sees here. Laws writes of NexPoint, “Recent investments should drive significant core earnings growth, which is reflected in the increased 4Q guidance range of $0.49-0.53 per share (up from $0.46-0.50 per share). The guidance incorporates the full quarter impact of the new 3Q investments as well as new mezz investments made in October. We are increasing our 4Q and 2021 estimates, and we have increased confidence in our forecast for a 1Q21 dividend increase, which we now forecast at $0.45 per share…”Following these sentiments, Laws puts a Strong Buy rating on NREF. His $18 price target suggest the stock has a 9% upside potential for the year ahead. (To watch Laws’ track record, click here)With 2 recent Buy reviews, the analyst consensus on NREF shares is a Moderate Buy. The stock’s $18 average price target matches Laws’, implying 9% growth. (See NREF stock analysis on TipRanks)To find good ideas for dividend stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
These 2 “Strong Buy” Penny Stocks Could Go Boom, Says Roth Capital
What kind of stocks stir up controversy like no other? Penny stocks. These tickers trading for less than $5 per share have earned a reputation as some of the most divisive names on Wall Street, with these plays either met with open arms or given the cold shoulder.It’s understandable why some investors are wary. Those opposed are quick to point out that there could be a very real reason these stocks are changing hands for pocket change, with the low share prices often masking obstacles like weak fundamentals or troubling headwinds. That said, others are drawn in by the sheer growth potential of penny stocks. The fact is that even minor share price appreciation can mean huge percentage gains, and thus, serious returns. What’s more, your money goes further with these bargain names.No matter which side you take, one thing is certain, due diligence is necessary before making any investment decisions. That’s where the experts come in, namely the analysts at Roth Capital. These pros bring experience and in-depth knowledge to the table.With this in mind, our focus turned to two penny stocks that have received a thumbs up from Roth Capital analysts. Running the tickers through TipRanks’ database, both have been cheered by the rest of the Street as well, as they boast a “Strong Buy” analyst consensus. Not to mention substantial upside potential is on the table.Cellectar Biosciences (CLRB)Leveraging its patented phospholipid drug conjugates (PDCs) delivery platform, Cellectar Biosciences develops cutting-edge treatments for cancer. Based on the potential of its drug candidate, CLR 131, and its $1.24 share price, Roth Capital thinks that now is the time to get in on the action.Representing the firm, analyst Jonathan Aschoff tells clients that he is optimistic about CLR 131, which is a small-molecule, targeted PDC designed to deliver cytotoxic radiation directly and selectively to cancer cells, in the lymphoplasmacytic lymphoma (LPL)/Waldenstrom’s macroglobulinemia (WM) indications. According to Aschoff, following its Type B guidance meeting with the FDA, “CLRB is prepared to initiate its first pivotal CLR 131 trial in LPL/WM after achieving a 100% ORR and 75% major response rate in four patients.” He points out that although CLRB just reported promising results in multiple myeloma (MM) (40% ORR in triple class refractory (TCR) patients at total body doses of at least 60mCi), LPL/WM was selected for the initial pivotal trial based on the very strong initial results and the lower competition for patients.“We view this as a prudent decision because NCCN compedia listing in MM is a mere peer-reviewed publication away, if first approved in LPL/WM. We also note that CLRB has steadily improved its dosing of CLR 131, essentially fractionating the doses so that higher total body doses are well tolerated,” Aschoff further explained. Adding to the good news, the therapy generated activity in preliminary Phase 1 unresectable brain tumors. Aschoff added, “Disease control was shown in two heavily pretreated patients with ependymomas, showing the drug’s ability to cross the blood brain barrier, and all doses through 60 mCi/m2 have exhibited a favorable safety profile.”To this end, Aschoff rates CLRB a Buy along with a $10 price target. Investors could be pocketing a gain of 713%, should this target be met in the twelve months ahead. (To watch Aschoff’s track record, click here)Are other analysts in agreement? They are. 5 Buys and no Holds or Sells have been issued in the last three months. So, the message is clear: CLRB is a Strong Buy. Given the $5.48 average price target, shares could soar 345% from current levels. (See CLRB stock analysis on TipRanks)Applied Genetic Technologies (AGTC)With vast gene therapy experience, Applied Genetic Technologies designs and constructs all critical gene therapy elements and brings them together to develop successful treatments for patients. Currently going for $4.50 apiece, Roth Capital believes this stock’s long-term growth narrative is strong.Firm analyst Zegbeh Jallah points out that recently released data for its XLRP gene therapy program, which is expected to enter pivotal studies in Q1 2021, reaffirmed his bullish thesis. “Despite the market not fully appreciating the data given how the stock traded, we continue to believe that the results suggest that AGTC could have a best-in-class therapy, which is supportive of the planned pivotal efforts,” he explained.Providing an update on the results of the Phase 1/2 XLRP study, using the FDA’s criteria, AGTC evaluated responses at 12 months in the lower dose groups (2 and 4), and 6 months in the higher dose groups (5 and 6). According to Jallah, “initial responses were observed in dose Groups 2, 3, 4, 5 and 6, with impressive response durability even at 12 months.”On top of this, at 6 months, the dose used in Group 5 resulted in a 43% response rate or a 57% response rate if excluding a patient not meeting the enrollment criteria. In Group 6, a response rate of 50% was observed, or 100% excluding patients not meeting the enrollment criteria.Jallah added, “All measurements were obtained in the 36 perimetry grid, which we believe should make it easier to preselect loci likely to respond. Although BCVA is not the primary endpoint, BCVA improvements, which can capture changes in the central region, were maintained at 12 months.”Even though some investors have expressed concern about Meira’s competing therapy, Jallah believes AGTC’s technology could have a leg up. “Overall, we believe that the data from both companies is strongly indicative of the efficacy potential of gene therapy for inherited retinal disease, and although differences in the study design makes direct comparisons difficult, we believe that AGTC could have a competitive advantage heading into pivotal studies,” he commented.In line with his optimistic approach, Jallah reiterated a Buy rating and $30 price target, indicating 568% upside potential. (To watch Jallah’s track record, click here)All in all, other analysts echo Jallah’s sentiment. 5 Buys and zero Holds or Sells add up to a Strong Buy consensus rating. The average price target of $18.25 is less aggressive than Jallah’s but still leaves room for upside potential of 306%. (See AGTC stock analysis on TipRanks)To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
5 of the Most Shorted Stocks of December
Instead of betting on stock prices to rise, short sellers take the opposite side of the trade and profit when stock prices fall. Rising short interest can be a red flag for investors, but it can also set up a phenomenon known as a short squeeze. Short squeezes are large, short-term spikes in a stock that can occur when short sellers exit their positions all at once by buying shares of stock.CBD, a non-psychoactive component of the Cannabis plant, however, does not fall under the Narcotic Laws of Europe, as far as it complies to certain criteria. In Germany, however, the online shop CBDKaufen.com has asked the "Federal Institute for Drugs and Medical Devices" (BfArM), the body responsible for declaring the legal status of products in Germany, whether or not CBD-Oils is legal in Germany and if CBD products can be sold freely in Germany. ]]>